Meeting News CoveragePerspectivePublication Exclusive

Chemotherapy did not increase risk for AML, MDS in early breast cancer

HemOnc Today, October 25, 2012
Adjuvant chemotherapy for early breast cancer did not increase the risk for acute myeloid leukemia and myelodysplastic syndrome, according to results…
Meeting News CoveragePerspectivePublication Exclusive

Racial, ethnic disparities identified in breast cancer care

HemOnc Today, October 25, 2012
SAN FRANCISCO — Despite established consensus, guidelines and treatment protocols, researchers observed racial and ethnic disparities in…
Meeting News Coverage

Blood leukocyte changes matched those in breast tumor stroma

HemOnc Today, October 25, 2012
SAN FRANCISCO — Alterations observed in peripheral blood leukocyte populations in breast cancer were similar to those found in the primary…
Meeting News CoveragePerspectivePublication Exclusive

Program designed to meet survivors’ medical, psychosocial needs

HemOnc Today, October 25, 2012
The Johns Hopkins Breast Cancer Survivorship program incorporates a multidisciplinary strategy that patients said helped them transition away from…
Meeting News CoveragePerspectivePublication Exclusive

Vaccine benefited patients with low expression of HER-2 tumors

HemOnc Today, October 25, 2012
Vaccination with the hybrid peptide AE37 demonstrated clinical benefit in patients with breast cancer, particularly those who have low…
Meeting News Coverage

IORT may yield significant savings over other approaches

HemOnc Today, October 1, 2012
SAN FRANCISCO — The use of intraoperative radiotherapy instead of other more common radiotherapy approaches could generate significant cost…
Meeting News CoveragePerspectivePublication Exclusive

Pooled analysis showed excellent outcomes after surgery, APBI

HemOnc Today, October 1, 2012
SAN FRANCISCO — Patients who underwent breast-conserving surgery and accelerated partial-breast irradiation experienced excellent outcomes…
Meeting News CoveragePerspectivePublication Exclusive

Everolimus linked to significant clinical benefit in ER-positive breast cancer

HemOnc Today, October 1, 2012
SAN FRANCISCO — Postmenopausal women with ER-positive breast cancer who were treated with the mTOR inhibitor everolimus plus exemestane had…
Meeting News CoveragePerspectivePublication Exclusive

Addition of everolimus improved PFS in postmenopausal patients

HemOnc Today, October 1, 2012
SAN FRANCISCO — The addition of the mTOR inhibitor everolimus to exemestane therapy significantly improved PFS in patients with advanced…
Meeting News CoveragePerspectivePublication Exclusive

Multicatheter brachytherapy linked to long-term disease control rates

HemOnc Today, October 1, 2012
SAN FRANCISCO — The 10-year regional failure rate associated with multicatheter brachytherapy in a cohort of patients with stage I/II breast…